Compare JPMorgan Equity Premium Income ETF (JEPI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.64, while State Street SPDR S&P Biotech ETF trades at $154.23. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPI | XBI | |
|---|---|---|
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $59.88 | $164.28 |
52-Week Low | $55.29 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.39, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high income but has underperformed the S&P 500 due to sector underweighting and upside caps. Recent news highlights tax inefficiencies and competition from alternatives like SPYI and DIVO.
JEPI's 8% yield appeals to income-focused investors, but total return potential is limited in bull markets. Risks include tracking error, tax disadvantages in taxable accounts, and sector concentration. Analyst sentiment is mixed, with some favoring more dynamic covered-call ETFs for better risk-adjusted returns in current market conditions.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
